A bill to amend title XVIII of the Social Security Act to eliminate cost sharing for biosimilar biological products furnished under part B of the Medicare program during the first 5 years such products are marketed.
About This Bill
Committee
Latest Action · March 12, 2020
Read twice and referred to the Committee on Finance.